SELLAS Life Sciences Group, Inc. (SLS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director | 994.38k | -- | 1976 |
| Mr. John Thomas Burns CPA | Senior VP & CFO | 620.89k | -- | 1985 |
| Dr. Dragan Cicic M.D., MBA | Senior VP & Chief Development Officer | 659.36k | -- | 1963 |
| Ms. Stacy E. Yeung | VP of Legal Affairs, Head of Compliance & Corporate Secretary | -- | -- | -- |
| Mr. Andrew Elnatan | Senior VP of Regulatory Affairs, CMC & Quality | -- | -- | -- |
SELLAS Life Sciences Group, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 15
Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 15, 2025 at 8:00 PM UTC
SELLAS Life Sciences Group, Inc. Earnings Date